[1]
Ilić MP, Kiralj A, Markov B, Mijatov I, Mijatov S, Vučković N. Li-Fraumeni syndrome: a case report. Vojnosanitetski pregled. 2014 Dec:71(12):1159-62
[PubMed PMID: 25639008]
Level 3 (low-level) evidence
[2]
Fortuno C, James PA, Spurdle AB. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Human mutation. 2018 Dec:39(12):1764-1773. doi: 10.1002/humu.23656. Epub 2018 Oct 3
[PubMed PMID: 30240537]
[3]
Doyle MR, Johnston JM. A novel p.Gly187Arg TP53 variant appears to result in Li-Fraumeni syndrome. Pediatric hematology and oncology. 2018 Apr:35(3):203-207. doi: 10.1080/08880018.2018.1502852. Epub 2018 Sep 21
[PubMed PMID: 30239254]
[4]
Kaur RP, Vasudeva K, Kumar R, Munshi A. Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies. Current pharmaceutical design. 2018:24(30):3566-3575. doi: 10.2174/1381612824666180926095709. Epub
[PubMed PMID: 30255744]
[5]
Shibata A, Tsai YC, Press MF, Henderson BE, Jones PA, Ross RK. Clonal analysis of bilateral breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996 Apr:2(4):743-8
[PubMed PMID: 9816225]
[6]
Salem B, Hofherr S, Turner J, Doros L, Smpokou P. Childhood Rhabdomyosarcoma in Association With a RASopathy Clinical Phenotype and Mosaic Germline SOS1 Duplication. Journal of pediatric hematology/oncology. 2016 Nov:38(8):e278-e282
[PubMed PMID: 27258033]
[7]
Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, Bremer RC, Rosenberg PS, Savage SA. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016 Dec 1:122(23):3673-3681. doi: 10.1002/cncr.30248. Epub 2016 Aug 6
[PubMed PMID: 27496084]
[8]
Rana HQ, Gelman R, LaDuca H, McFarland R, Dalton E, Thompson J, Speare V, Dolinsky JS, Chao EC, Garber JE. Differences in TP53 Mutation Carrier Phenotypes Emerge From Panel-Based Testing. Journal of the National Cancer Institute. 2018 Aug 1:110(8):863-870. doi: 10.1093/jnci/djy001. Epub
[PubMed PMID: 29529297]
[9]
Lynch HT, McComb RD, Osborn NK, Wolpert PA, Lynch JF, Wszolek ZK, Sidransky D, Steg RE. Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome. Cancer. 2000 Jan 15:88(2):433-9
[PubMed PMID: 10640978]
Level 3 (low-level) evidence
[10]
O'Neill AF, Voss SD, Jagannathan JP, Kamihara J, Nibecker C, Itriago-Araujo E, Masciari S, Parker E, Barreto M, London WB, Garber JE, Diller L. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatric blood & cancer. 2018 Feb:65(2):. doi: 10.1002/pbc.26822. Epub 2017 Oct 27
[PubMed PMID: 29077256]
Level 3 (low-level) evidence
[11]
Barbosa OV, Reiriz AB, Boff RA, Oliveira WP, Rossi L. Angiosarcoma in previously irradiated breast in patient with Li-Fraumeni syndrome. A case report. Sao Paulo medical journal = Revista paulista de medicina. 2015 Mar-Apr:133(2):151-3. doi: 10.1590/1516-3180.2012.6740004. Epub 2014 Sep 26
[PubMed PMID: 25271877]
Level 3 (low-level) evidence
[12]
Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, Gallinger B, Naumer A, Kohlmann W, Novokmet A, Tabori U, Tijerin M, Greer ML, Finlay JL, Schiffman JD, Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. The Lancet. Oncology. 2016 Sep:17(9):1295-305. doi: 10.1016/S1470-2045(16)30249-2. Epub 2016 Aug 5
[PubMed PMID: 27501770]
Level 2 (mid-level) evidence
[13]
Zerdoumi Y, Lanos R, Raad S, Flaman JM, Bougeard G, Frebourg T, Tournier I. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage. Human molecular genetics. 2017 Jul 15:26(14):2591-2602. doi: 10.1093/hmg/ddx106. Epub
[PubMed PMID: 28369373]
[14]
Zhu Q, Wani G, Yao J, Patnaik S, Wang QE, El-Mahdy MA, Praetorius-Ibba M, Wani AA. The ubiquitin-proteasome system regulates p53-mediated transcription at p21waf1 promoter. Oncogene. 2007 Jun 21:26(29):4199-208
[PubMed PMID: 17224908]
[15]
Prives C, Manfredi JJ. The p53 tumor suppressor protein: meeting review. Genes & development. 1993 Apr:7(4):529-34
[PubMed PMID: 8096197]
[16]
Tabori U, Nanda S, Druker H, Lees J, Malkin D. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer research. 2007 Feb 15:67(4):1415-8
[PubMed PMID: 17308077]
[17]
Zawlik I, Kita D, Vaccarella S, Mittelbronn M, Franceschi S, Ohgaki H. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain pathology (Zurich, Switzerland). 2009 Apr:19(2):188-94. doi: 10.1111/j.1750-3639.2008.00170.x. Epub 2008 May 6
[PubMed PMID: 18462472]
[18]
Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. MDM2 SNP309 T}G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. International journal of cancer. 2007 Feb 1:120(3):563-5
[PubMed PMID: 17096342]
[19]
Bakhuizen JJ, Velthuizen ME, Stehouwer S, Bleiker EM, Ausems MG. Genetic counselling of young women with breast cancer for Li-Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals. Familial cancer. 2019 Apr:18(2):231-239. doi: 10.1007/s10689-018-0103-5. Epub
[PubMed PMID: 30238178]
Level 3 (low-level) evidence
[20]
Greer MC. Imaging of cancer predisposition syndromes. Pediatric radiology. 2018 Aug:48(9):1364-1375. doi: 10.1007/s00247-018-4113-0. Epub 2018 Aug 4
[PubMed PMID: 30078044]
[21]
Adeyanju MA, Ilori AA. Multiple primary tumors. Nigerian journal of clinical practice. 2017 Oct:20(10):1346-1349. doi: 10.4103/njcp.njcp_432_16. Epub
[PubMed PMID: 29192643]
[22]
Giavedoni P, Ririe M, Carrera C, Puig S, Malvehy J. Familial Melanoma Associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: Total-body Digital Photography, Dermoscopy and Confocal Microscopy. Acta dermato-venereologica. 2017 Jun 9:97(6):720-723. doi: 10.2340/00015555-2639. Epub
[PubMed PMID: 28218344]
[23]
Kumar P, Gill RM, Phelps A, Tulpule A, Matthay K, Nicolaides T. Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives. Cureus. 2018 Apr 24:10(4):e2527. doi: 10.7759/cureus.2527. Epub 2018 Apr 24
[PubMed PMID: 29946497]
[24]
Guha T, Malkin D. Inherited TP53 Mutations and the Li-Fraumeni Syndrome. Cold Spring Harbor perspectives in medicine. 2017 Apr 3:7(4):. doi: 10.1101/cshperspect.a026187. Epub 2017 Apr 3
[PubMed PMID: 28270529]
Level 3 (low-level) evidence
[25]
Weitzel JN, Chao EC, Nehoray B, Van Tongeren LR, LaDuca H, Blazer KR, Slavin T, Facmg DABMD, Pesaran T, Rybak C, Solomon I, Niell-Swiller M, Dolinsky JS, Castillo D, Elliott A, Gau CL, Speare V, Jasperson K. Somatic TP53 variants frequently confound germ-line testing results. Genetics in medicine : official journal of the American College of Medical Genetics. 2018 Aug:20(8):809-816. doi: 10.1038/gim.2017.196. Epub 2017 Nov 30
[PubMed PMID: 29189820]
[26]
O'Shea R, Clarke R, Berkley E, Giffney C, Farrell M, O'Donovan E, Gallagher DJ. Next generation sequencing is informing phenotype: a TP53 example. Familial cancer. 2018 Jan:17(1):123-128. doi: 10.1007/s10689-017-0002-1. Epub
[PubMed PMID: 28509937]
[27]
Penkert J, Schlegelberger B, Steinemann D, Gadzicki D. No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways. Familial cancer. 2012 Dec:11(4):601-6. doi: 10.1007/s10689-012-9556-0. Epub
[PubMed PMID: 22864638]
[28]
Petr EJ, Else T. Adrenocortical carcinoma (ACC): When and why should we consider germline testing? Presse medicale (Paris, France : 1983). 2018 Jul-Aug:47(7-8 Pt 2):e119-e125. doi: 10.1016/j.lpm.2018.07.004. Epub 2018 Aug 10
[PubMed PMID: 30104051]
[29]
Warby M, Wakefield CE, Vetsch J, Tucker KM. Families' and health care professionals' attitudes towards Li-Fraumeni syndrome testing in children: A systematic review. Clinical genetics. 2019 Jan:95(1):140-150. doi: 10.1111/cge.13442. Epub 2018 Oct 10
[PubMed PMID: 30191952]
Level 1 (high-level) evidence
[30]
Mai PL, Khincha PP, Loud JT, DeCastro RM, Bremer RC, Peters JA, Liu CY, Bluemke DA, Malayeri AA, Savage SA. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort. JAMA oncology. 2017 Dec 1:3(12):1640-1645. doi: 10.1001/jamaoncol.2017.1350. Epub
[PubMed PMID: 28772286]
[31]
Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, Pachet C, Mathieu MC, Marsiglia H, Bourgier C. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiation oncology (London, England). 2010 Nov 8:5():104. doi: 10.1186/1748-717X-5-104. Epub 2010 Nov 8
[PubMed PMID: 21059199]
[32]
Pal T, Brzosowicz J, Valladares A, Wiesner GL, Laronga C. Identification and Management of TP53 Gene Carriers Detected Through Multigene Panel Testing. Southern medical journal. 2017 Oct:110(10):643-648. doi: 10.14423/SMJ.0000000000000711. Epub
[PubMed PMID: 28973705]
[33]
Schon K, Tischkowitz M. Clinical implications of germline mutations in breast cancer: TP53. Breast cancer research and treatment. 2018 Jan:167(2):417-423. doi: 10.1007/s10549-017-4531-y. Epub 2017 Oct 16
[PubMed PMID: 29039119]
[34]
Pederson HJ, Padia SA, May M, Grobmyer S. Managing patients at genetic risk of breast cancer. Cleveland Clinic journal of medicine. 2016 Mar:83(3):199-206. doi: 10.3949/ccjm.83a.14057. Epub
[PubMed PMID: 26974991]
[36]
McEvoy M, Robison N, Manley P, Yock T, Konopka K, Brown RE, Wolff J, Green AL. Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma. Journal of pediatric hematology/oncology. 2017 Nov:39(8):e473-e475. doi: 10.1097/MPH.0000000000000965. Epub
[PubMed PMID: 28859040]
[37]
Jhaveri AP, Bale A, Lovick N, Zuckerman K, Deshpande H, Rath K, Schwartz P, Hofstatter EW. The benefit and burden of cancer screening in Li-Fraumeni syndrome: a case report. The Yale journal of biology and medicine. 2015 Jun:88(2):181-5
[PubMed PMID: 26029016]
Level 3 (low-level) evidence
[38]
Valdez JM, Walker B, Ogg S, Gattuso J, Alderfer MA, Zelley K, Ford CA, Baker JN, Mandrell BN, Nichols KE. Parent-child communication surrounding genetic testing for Li-Fraumeni syndrome: Living under the cloud of cancer. Pediatric blood & cancer. 2018 Nov:65(11):e27350. doi: 10.1002/pbc.27350. Epub 2018 Jul 15
[PubMed PMID: 30009566]
[39]
Potapov AA, Abdilatipov AA, Okhlopkov VA, Gavrilov AG, Zakharova NE, Goryaynov SA, Kobyakov GL, Absalyamova OV, Kravchuk AD, Kulikov AS, Shugay SV, Nikitin PV, Batalov AI, Shelygin YA, Lyubchenko LN, Aliev MD, Spallone A. [Li-Fraumeni syndrome in a patient with multiple anaplastic oligodendrogliomas of the brain (a case report and literature review)]. Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko. 2018:82(4):87-96. doi: 10.17116/neiro201882487. Epub
[PubMed PMID: 30137042]
Level 3 (low-level) evidence
[40]
Ring KL, Garcia C, Thomas MH, Modesitt SC. Current and future role of genetic screening in gynecologic malignancies. American journal of obstetrics and gynecology. 2017 Nov:217(5):512-521. doi: 10.1016/j.ajog.2017.04.011. Epub 2017 Apr 12
[PubMed PMID: 28411145]
[41]
McBride KA, Ballinger ML, Schlub TE, Young MA, Tattersall MHN, Kirk J, Eeles R, Killick E, Walker LG, Shanley S, Thomas DM, Mitchell G. Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? Familial cancer. 2017 Jul:16(3):423-432. doi: 10.1007/s10689-016-9964-7. Epub
[PubMed PMID: 28124295]
[42]
Bester J, Sabatello M, van Karnebeek CDM, Lantos JD. Please Test My Child for a Cancer Gene, but Don't Tell Her. Pediatrics. 2018 Apr:141(4):. doi: 10.1542/peds.2017-2238. Epub 2018 Mar 13
[PubMed PMID: 29535250]